These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 21817114

  • 1. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
    Stolfi C, Caruso R, Franzè E, Rizzo A, Rotondi A, Monteleone I, Fantini MC, Pallone F, Monteleone G.
    Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
    [Abstract] [Full Text] [Related]

  • 2. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y, Swierczewska M, Kim TH, Lim SM, Eom HN, Park JH, Na DH, Kim K, Lee KC, Pomper MG, Lee S.
    J Control Release; 2015 Dec 28; 220(Pt B):671-81. PubMed ID: 26381901
    [Abstract] [Full Text] [Related]

  • 3. Icariin sensitizes human colon cancer cells to TRAIL‑induced apoptosis via ERK‑mediated upregulation of death receptors.
    Kim B, Seo JH, Lee KY, Park B.
    Int J Oncol; 2020 Mar 28; 56(3):821-834. PubMed ID: 32124960
    [Abstract] [Full Text] [Related]

  • 4. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
    Guo X, Meng Y, Sheng X, Guan Y, Zhang F, Han Z, Kang Y, Tai G, Zhou Y, Cheng H.
    Anticancer Drugs; 2017 Jan 28; 28(1):66-74. PubMed ID: 27603596
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin.
    Hwang JS, Lee HC, Oh SC, Lee DH, Kwon KH.
    Tumour Biol; 2015 Nov 28; 36(11):8819-29. PubMed ID: 26063410
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.
    Gupta SC, Reuter S, Phromnoi K, Park B, Hema PS, Nair M, Aggarwal BB.
    J Biol Chem; 2011 Jan 14; 286(2):1134-46. PubMed ID: 21078664
    [Abstract] [Full Text] [Related]

  • 9. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
    Qiao X, Wang X, Shang Y, Li Y, Chen SZ.
    Cancer Commun (Lond); 2018 Jul 03; 38(1):43. PubMed ID: 29970185
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
    Chen L, Meng Y, Sun Q, Zhang Z, Guo X, Sheng X, Tai G, Cheng H, Zhou Y.
    Cell Death Dis; 2016 Aug 11; 7(8):e2334. PubMed ID: 27512955
    [Abstract] [Full Text] [Related]

  • 12. Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.
    Na YJ, Lee DH, Kim JL, Kim BR, Park SH, Jo MJ, Jeong S, Kim HJ, Lee SY, Jeong YA, Oh SC.
    Int J Biochem Cell Biol; 2017 Aug 11; 89():147-156. PubMed ID: 28624529
    [Abstract] [Full Text] [Related]

  • 13. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL.
    Clin Cancer Res; 2008 May 15; 14(10):3168-76. PubMed ID: 18483385
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H, Zhao F, Yu S, He J, Deng L, Yi C, Huang Y.
    Int J Mol Med; 2012 Nov 15; 30(5):1087-94. PubMed ID: 22922573
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.